GRAIL Dividendos y recompras
Dividendo controles de criterios 0/6
GRAIL no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-15.8%
Rendimiento de la recompra
| Rendimiento total para el accionista | -15.8% |
| Rendimiento futuro de los dividendos | 0% |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
Actualización de narrativa • Sep 03
GRAL: Regulatory And Reimbursement Uncertainty Will Drive Future Downside Risk
Analysts have raised the GRAIL fair value estimate from $56 to $60, citing Street research that points to larger addressable markets, solid test volume trends, and mixed but generally constructive sector views reflected in recent price target updates between $60 and $88. Analyst Commentary Street research on GRAIL over the past few months shows a mix of optimism about long term opportunities and caution about near term execution and valuation.
Actualización de narrativa • Aug 17
GRAL: Future Returns Will Depend On Trial Decisions And Reimbursement Progress
GRAIL's updated analyst price target has risen from $66 to about $72, with analysts pointing to a larger addressable diagnostics market, stronger volume trends, and expectations for higher future P/E multiples, while also acknowledging slightly tighter profit margin assumptions and sector wide risk sentiment. Analyst Commentary Recent research on GRAIL gives a split picture, with some bullish analysts lifting price targets and others staying cautious on execution risk and reimbursement timelines.Seeking Alpha • Aug 12
GRAIL: Looking Beyond The NHS-Galleri Headline
Summary GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms. GRAL's valuation remains modest relative to peers and the size of the MCED opportunity, meaning positive news from the AdCom in September could see the stock move significantly higher. Read the full article on Seeking AlphaActualización de narrativa • Aug 03
GRAL: Regulatory And Lawsuit Overhang Will Drive Future Downside Risk
GRAIL's analyst price target has shifted modestly in recent weeks, with research citing large addressable markets, strong volume trends, better pricing, and ongoing payor and regulatory uncertainty that keeps some firms on the sidelines while others lift targets into the $60 to $88 range. Analyst Commentary Recent Street research on GRAIL highlights a split view.
Actualización de narrativa • Jul 20
GRAL: Future Reimbursement Progress Will Drive Confidence Despite Trial And Legal Headwinds
GRAIL's analyst price target has shifted from $80 to $88, with analysts citing large addressable markets, strong volume trends, and improving pricing, while still acknowledging a more challenging near-term risk and reward setup and a mixed sector backdrop. Analyst Commentary Recent Street research on Grail reflects a mix of optimism around the company’s testing portfolio and caution around sector and reimbursement risks.Actualización de narrativa • Jul 06
GRAL: Future Reimbursement Progress Will Drive Confidence After Trial Setback
The updated analyst price target for GRAIL has shifted from $130 to $80, reflecting a more cautious stance from analysts who highlight regulatory uncertainty around multi cancer early detection tests and the need for clearer reimbursement support before the story can fully play out. Analyst Commentary Recent Street research on Grail has centered on how quickly the company can broaden use of its Galleri multi cancer early detection test beyond the self pay market and into reimbursed channels.Actualización de narrativa • Jun 22
GRAL: Future Returns Will Hinge On Trial Outcomes And Reimbursement Clarity
The GRAIL analyst price target has been modestly reset, slipping from $66.86 to $66.00 as analysts factor in a slightly higher discount rate and ongoing uncertainty around regulatory review and payor reimbursement for the Galleri test. Analyst Commentary Recent Street research on GRAIL points to a cautious but engaged stance, with Goldman Sachs and several other firms sitting at the middle of the spectrum as they weigh the commercial opportunity for the Galleri test against open questions on regulation and reimbursement.Artículo de análisis • Jun 20
GRAIL (GRAL) Stock Could Be 4.7% Undervalued After NHS Galleri Trial Setback
GRAIL (GRAL) is under pressure after disclosing that its NHS Galleri trial did not achieve the expected statistically significant reduction in late stage cancers, triggering multiple securities class action lawsuits and sharp investor concern. See our latest analysis for GRAIL. The failed NHS Galleri trial and subsequent lawsuits came after a sharp one day drop earlier in the year. Since then, the stock has shown mixed momentum, with a 90 day share price return of 36.08%, a year to date share...Actualización de narrativa • Jun 04
GRAL: Future Returns Will Reflect Trial Evidence And Reimbursement Progress
GRAIL's analyst price target has been reduced by about $1 per share as analysts factor in more balanced assumptions on reimbursement progress, profitability, and long-term P/E expectations, following a mix of cautious initiations and price target changes across the Street. Analyst Commentary Recent Street research on GRAIL points to a more balanced stance, with a mix of cautious initiations, price target reductions, and a smaller number of positive adjustments that keep expectations in check.Artículo de análisis • May 08
Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results
A week ago, GRAIL, Inc. ( NASDAQ:GRAL ) came out with a strong set of first-quarter numbers that could potentially lead...Actualización de narrativa • May 07
GRAL: Future Returns Will Reflect Trial Outcomes And Reimbursement Progress
Narrative Update on GRAIL Analysts have trimmed their average price target for GRAIL by incorporating lower profit margin assumptions and a slightly higher future P/E of about 101x, following mixed reactions to recent study readouts and reimbursement uncertainty. Analyst Commentary Recent research updates on GRAIL reflect a split tape, with some firms trimming price targets after the NHS Galleri readout and reimbursement uncertainty, while others still see room for upside based on the company’s test portfolio and addressable market.Actualización de narrativa • Apr 19
GRAL: Future Returns Will Depend On Upcoming FDA Approval Decision
Analysts have trimmed GRAIL's average price target to about $67.71 from $72.40. They cited updated models that factor in recent price target cuts following the NHS-Galleri topline readout and lingering uncertainty around broad reimbursement, even as revenue growth and margin assumptions are slightly adjusted.Actualización de narrativa • Apr 05
GRAL: Future Returns Will Hinge On Upcoming Regulatory And Coverage Milestones
Narrative Update on GRAIL The analyst price target for GRAIL has been reduced by $11.00. This change reflects recent cuts across firms citing the NHS Galleri study missing its primary endpoint and greater uncertainty around broad reimbursement, even as analysts still reference GRAIL's position in multi cancer early detection and upcoming regulatory and coverage milestones.Actualización de narrativa • Mar 21
GRAL: Future Returns Will Depend On NHS Study Outcome
Narrative Update: GRAIL Analyst Price Target Shift The updated analyst fair value estimate for GRAIL has moved from $88.00 to $83.40 as analysts factor in lower published price targets following the NHS Galleri study missing its primary endpoint and increased uncertainty around broad reimbursement, while still modeling higher revenue, stronger profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research shows a mix of optimism and caution around GRAIL, with several firms revising price targets after the NHS Galleri study update and recent quarterly results.Nueva narrativa • Mar 08
Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection Potential
Catalysts About GRAIL GRAIL focuses on multi cancer early detection through its Galleri screening test and related clinical programs. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Mar 06
GRAL: Future Returns Will Hinge On NHS Study And FDA Decision
The analyst fair value estimate for Grail has been trimmed from $114.50 to $88.00 as analysts factor in lower revenue growth and profit margin assumptions following the NHS Galleri readout and increased uncertainty around broad reimbursement. Analyst Commentary Street research on Grail has shifted meaningfully following the NHS Galleri top line readout, with several firms reducing price targets and reassessing the risk and reward profile around Galleri adoption and reimbursement.Nueva narrativa • Feb 22
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Catalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Feb 20
GRAL: Future Returns Will Hinge On Upcoming NHS Trial Readout
The average analyst price target for Grail has edged down by $0.50 to about $114.50, as analysts balance optimism around upcoming trial readouts and potential regulatory milestones with a more cautious stance after the stock's very large move earlier in 2025 and ongoing execution risks. Analyst Commentary Recent research on Grail reflects a mix of enthusiasm for its position in multi cancer early detection and caution around valuation and execution timelines.Actualización de narrativa • Feb 04
GRAL: Future Returns Will Depend On NHS Readout And Execution Consistency
Narrative Update Analysts have lifted their price target on GRAIL from $105 to $115, citing refreshed models that reflect updated assumptions for growth, margins and future P/E. Recent research highlights steady execution, the long term Galleri opportunity, and the absence of thesis changing developments in recent results.Actualización de narrativa • Jan 20
GRAL: Future Returns Will Hinge On NHS Trial And Execution Risks
Analysts have nudged their price target on GRAIL up to $110 from $85, citing steady execution, a modest Q4 revenue beat, and the longer term opportunity for the Galleri test, despite the inherent risks that come with new technologies. Analyst Commentary Analysts see GRAIL's recent results as an incremental step rather than a major reset, with views split between confidence in execution and caution around key milestones like the NHS Galleri trial readout.Actualización de narrativa • Jan 06
GRAL: Long Term MCED Opportunity And Execution Risks Will Shape Future Returns
Analysts have raised their price target range for GRAIL to about $85 from around $38, citing updated post-Q3 estimates and what they view as a significant long-term commercial opportunity for the Galleri multi-cancer early detection test, while also highlighting the risks associated with this type of novel technology. Analyst Commentary Bullish Takeaways Bullish analysts see the increase in the price target range to about $85 as a reflection of what they view as a sizeable commercial runway for the Galleri multi cancer early detection test over the long term.Actualización de narrativa • Dec 16
GRAL: Future MCED Policy Shifts Will Drive Upside Despite Execution Risks
Analysts have raised their price target on GRAIL to $105 from $96.67, citing updated post earnings estimates and growing confidence in the long term commercial potential of the Galleri multi cancer early detection platform, despite ongoing technology and regulatory risks. Analyst Commentary Recent Street research reflects a meaningful reset in expectations for GRAIL, with multiple price target increases grounded in updated post earnings models and a clearer view of Galleri's commercial runway.Actualización de narrativa • Dec 01
GRAL: Risks From Clinical Data and Execution Will Remain a Key Concern
Analysts have raised their price target for GRAIL from approximately $90 to $97 per share, citing strengthened confidence in the company’s long-term growth prospects. This outlook is driven by recent developments and opportunities in multi-cancer early detection.Actualización de narrativa • Nov 17
GRAL: Confidence Will Increase With Upcoming Clinical Data and Legislative Progress
Analysts have raised their price target for GRAIL from $61.50 to $90.00. This change reflects increased confidence in the company’s long-term prospects and growth potential, following recent updates and a positive outlook on its multi-cancer early detection technology.Actualización de narrativa • Nov 01
GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory Shifts
Analysts have raised GRAIL's fair value estimate from $56.50 to $61.50 per share, citing greater confidence in the company's platforms, ongoing clinical milestones, and evolving market opportunities as key drivers for the upward revision. Analyst Commentary Bullish Takeaways Bullish analysts highlight growing confidence in GRAIL's platforms.Actualización de narrativa • Oct 18
FDA Approval And NHS Studies Will Transform Cancer Detection
Analysts have raised their price target on GRAIL significantly, from $43 to $75. They cite growing confidence in the company's platforms, anticipated improvements in test performance, and the potential impact of future legislative changes as reasons for this adjustment.Actualización de narrativa • Oct 04
FDA Approval And NHS Studies Will Transform Cancer Detection
Analysts have raised their price target for GRAIL from $40.50 to $56.50. They cite strengthened confidence in the company's platforms, positive expectations for future study results, and anticipation of supportive legislative developments.Nueva narrativa • Jun 15
Overvaluation Risks And NHS Trials Will Spur Future Resilience
Market optimism may overestimate Galleri's near-term adoption and pricing power due to regulatory, payer, and competitive pressures.Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de GRAL han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de GRAL han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de GRAIL vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (GRAL) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.1% |
| Media de la industria (Biotechs) | 2.2% |
| Analista de previsiones (GRAL) (hasta 3 años) | 0% |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de GRAL en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de GRAL en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de GRAL para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que GRAL no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/12 01:38 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
GRAIL, Inc. está cubierta por 14 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Kyle Mikson | Canaccord Genuity |